AbCellera Biologics Inc Ordinary Shares ABCL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ABCL is a good fit for your portfolio.
News
-
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
-
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
-
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
-
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
-
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
-
AbCellera Announces Resignation of Board Member
-
AbCellera to Present at Upcoming Investor Conferences in March
-
AbCellera Reports Full Year 2023 Business Results
Trading Information
- Previous Close Price
- $3.87
- Day Range
- $3.83–4.01
- 52-Week Range
- $3.79–8.05
- Bid/Ask
- $3.93 / $4.01
- Market Cap
- $1.17 Bil
- Volume/Avg
- 1.1 Mil / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 30.49
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
AbCellera Biologics Inc is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company’s experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 586
- Website
- https://www.abcellera.com
Comparables
Valuation
|
Metric
|
ABCL
|
301080
|
OABI
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 28.00 | — |
Price/Book Value | 1.01 | 1.69 | 1.74 |
Price/Sales | 30.49 | 8.23 | 13.66 |
Price/Cash Flow | — | 29.78 | — |
Price/Earnings
ABCL
301080
OABI
Financial Strength
|
Metric
|
ABCL
|
301080
|
OABI
|
|---|---|---|---|
Quick Ratio | 6.93 | 15.32 | 3.93 |
Current Ratio | 7.33 | 16.62 | 4.11 |
Interest Coverage | — | 41.71 | — |
Quick Ratio
ABCL
301080
OABI
Profitability
|
Metric
|
ABCL
|
301080
|
OABI
|
|---|---|---|---|
Return on Assets (Normalized) | −6.10% | 5.69% | −7.75% |
Return on Equity (Normalized) | −7.74% | 6.08% | −9.40% |
Return on Invested Capital (Normalized) | −10.03% | 5.05% | −9.83% |
Return on Assets
ABCL
301080
OABI
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fsmtxvbkyq | Bztg | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ykrvckrw | Zxtdbwr | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Psprqjp | Cfcvlr | $98.8 Bil | |
MRNA
| Moderna Inc | Cckrzwd | Zxlt | $38.8 Bil | |
ARGX
| argenx SE ADR | Cwsqcrfb | Scfp | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Sgxwcwsr | Xlcnv | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ggjkcddf | Mlygzm | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kmbxsllyc | Qwfpz | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xcbstwpjl | Wvylky | $12.4 Bil | |
INCY
| Incyte Corp | Yydhvfjwb | Jhytdw | $11.9 Bil |